NewsBenzingaCEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10% CEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10% Benzinga 2026.10.26 12:07 (GMT+0) Open on Benzinga Other news Openai CEO Sam Altman Says AI Revolution Without Ex-Nvidia CEO Huang Is ‘Hard To Imagine’ SpaceX Stock to Double? Analyst Says Company Completed ‘The Missing Piece of the Reusability Puzzle’ What Is Going on With Supermicro Stock on Monday? Bernie Sanders Tells Big Tech Their $3 Trillion in AI Debt Rides on a 'High-Stakes Gamble' — If It Fails, 'Don't Come Begging to Taxpayers' Breakup Blues: Another Firm Downgrades Nvidia Stock Following Jensen’s Huang Resignation Global Mofy Stock Nearly Triples as Investors Eye Its Latest AI Investment
Bernie Sanders Tells Big Tech Their $3 Trillion in AI Debt Rides on a 'High-Stakes Gamble' — If It Fails, 'Don't Come Begging to Taxpayers'